Acidic, Neutral and Alkaline Drug Analysis

For a simple weak acid HA, pH = pKa + log10([A−]/[HA]). Lower pH favours the protonated acid; higher pH favours the anion. For a weak base, apply the relationship to its conjugate acid BH+: pH = pKa + log10([B]/[BH+]). Higher pH favours the unprotonated base.

At pH equal to pKa, the relevant pair is present in equal proportions under the model assumptions. Two pH units to one side gives a ratio of about 100:1, or approximately 99% of the favoured form. This describes ionisation, not a guaranteed 99% analytical recovery.

A weak acid can have a pKa above seven, while the conjugate acid of a weak base can have a pKa below seven. Classifying a compound as acidic or basic solely by whether its pKa is below or above seven confuses strength with functional-group behaviour.

Not every organic drug has an ionisable group relevant across the extraction range. Others have several groups, can form zwitterions or remain permanently charged. A single-pKa model may then be incomplete or unsuitable.

Un-ionised species often partition more readily into a suitable organic phase, but molecular polarity and solvent interactions still matter. Stability, protein binding and emulsions can also influence measured recovery. Select supported conditions rather than treating a pH rule as a full extraction protocol.

Acidic extraction can favour suitable weak-acid targets in their un-ionised form and can also recover some neutral compounds. Basic extraction can favour suitable unprotonated bases. A neutral fraction is an operational part of a method, not a universal chemical family containing every benzodiazepine.

Benzodiazepines differ in ionisable groups and stability. Some are weak bases and others have additional acidic behaviour. Do not assign all of them an isoelectric extraction pH or assume that one solvent is always best across the class.

Paracetamol has a weakly acidic phenolic group. Being largely un-ionised at acid pH does not make it extremely non-polar or guarantee efficient recovery into any chosen solvent. Its extraction must be demonstrated for the actual method and matrix.

Basic drugs also differ. An opioid, antidepressant and amphetamine need not have equal recovery under one alkaline condition. Morphine and related compounds can have more than one relevant ionisable group; excessive pH may introduce another charge state or stability problem.

Solvent selection considers distribution, phase separation, safety and compatibility with later analysis. Layer position depends on density. MTBE, ethyl acetate and chlorinated solvents are not interchangeable, but there is no universal prohibition on a solvent simply because a fraction is labelled neutral.

A broad SPE method can cover targets that once occupied several classical fractions. Separate aliquots may still be needed for particular targets or preservation requirements. Validate coverage rather than assuming that three fractions are always necessary or that one broad extract includes everything.

Suspected drug-facilitated crime can involve alcohol, prescribed medicines, illicit substances and mixtures. There is no universal signature drug or concentration proving clandestine administration. Voluntary use and opportunistic exploitation can also be relevant to an investigation.

Prompt collection of suitable blood and urine can improve the opportunity for detection, but detection windows vary by target, dose, method and individual factors. A rigid twelve-hour deadline or a claim that every case fails after forty-eight hours is inaccurate.

Record the alleged event time, collection time, symptoms, medicines, reported use and treatment. Consent, examination and evidence handling follow the applicable professional and legal requirements. Toxicology should support a careful investigation without making assumptions about the reporting person's credibility.

A routine immunoassay panel may miss relevant compounds or low concentrations. The laboratory needs the case question to select appropriate targeted or broader testing. A negative screen does not establish that no drug was present during the event.

Hair can sometimes add retrospective evidence after an appropriately planned interval, but it is not an automatic rescue for every delayed report. Growth, incorporation, external contamination and sensitivity limit interpretation. A negative later hair result does not overrule a valid positive urine finding.

Symptoms, reported drink history and analytical findings should be documented separately. A positive result can support an exposure assessment without establishing how a substance entered a drink or whether it caused incapacity at the alleged event time.

Immunoassays use antibody responses calibrated for particular targets or classes. Cross-reactivity can produce unexpected positives, while limited response to another class member can produce a negative result despite its presence. The word “opiates” on a panel does not guarantee detection of all synthetic opioids.

Presumptive colour reactions can also respond to several compounds and mixtures. Reagent condition, concentration and matrix affect the observation. A colour alone should not be reported as unique identity or used to infer a drug's concentration.

Suitable chromatographic and spectrometric methods can provide more selective evidence. Identification requirements depend on the complete validated scheme and acquisition mode. Two MRM transitions and an internal standard are not a universal standalone proof for every analyte.

Quantification requires a demonstrated calibration model and range, appropriate controls, matrix assessment and correct preparation factors. Internal standards may help address variability when they behave suitably. Their presence does not remove every error or prove an otherwise ambiguous identity.

Programme cutoffs, analytical reporting limits and clinical decision concentrations are different concepts. SAMHSA federal workplace rules should not be copied as universal serum or post-mortem thresholds, nor attributed without evidence to every Indian laboratory.

State the compounds included in the assay and relevant limitations. A negative result for a target panel does not mean that every acidic, neutral and basic poison has been excluded. Consider additional methods when the suspected target is unstable, unusually polar or outside the routine acquisition.

After death, tissue release, diffusion, degradation and local contamination can change drug concentrations. Lipophilic basic drugs can be particularly affected, but the magnitude and direction depend on the compound and circumstances. Central and peripheral blood may differ.

Separate documented sampling sites help interpretation. A cardiac-to-peripheral ratio describes those measured specimens; it does not provide a correction factor for a living blood concentration. A ratio near one also does not prove that neither specimen changed.

Peripheral blood is often preferred for post-mortem interpretation, but it is not automatically identical to the antemortem concentration. Compare the result with suitable post-mortem data and the broader case rather than directly applying a therapeutic plasma range from a living patient.

Vitreous can provide complementary evidence for suitable targets, but its distribution and analytical behaviour differ from blood. It is not a universally stable replacement for blood for all antidepressants or opioids. Method validation and matrix-specific interpretation remain necessary.

Concentration ranges overlap across therapeutic use, toxicity and fatalities. Tolerance, co-exposures, disease, survival time and treatment influence outcomes. A drug identification or apparently high concentration cannot alone establish cause of death or the manner in which the drug was administered.

Check the pH achieved in the actual specimen preparation rather than assuming that an added reagent always produces the intended condition. Matrix buffering can alter it. Excessive acid or base can damage targets, alter conjugates or change subsequent chromatographic behaviour.

Emulsions, adsorption and incomplete evaporation or reconstitution can affect recovery. A salt addition or alternative cleanup may help a particular method, but a fixed thirty-to-seventy-percent improvement cannot be promised without data. Changes require appropriate evaluation before case reporting.

Use controls that address preparation and measurement, and assess stability under the actual handling conditions. A suitable internal standard added after extraction cannot evaluate losses that happened beforehand. A control that passes for one drug does not necessarily establish every panel member's recovery.

Metabolites can support exposure interpretation but are not universal proof against contamination or proof of a specific administration event. Some drugs share metabolites, and post-collection changes can complicate patterns. Interpret the parent–metabolite relationship for the actual compound and specimen.

US identification and validation standards, UK laboratory guidance and the applicable requirements in India and other countries support the same need for transparent analytical reasoning. The legal use of a result varies by jurisdiction. Report what the evidence establishes without converting a finding into a conclusion about consent, intent or guilt.

Related reading: Classical Extraction: Stas-Otto and Ammonium Sulphate Methods.

Related reading: Modern Extraction: SPE, SPME and Accelerated Solvent Extraction.

Related reading: Drug Metabolism, Distribution and Metabolite Identification.